Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
UCB [BE0003739530/UCB]   
[20/05/2019]

UCB : UCB Media Room: Nayzilam US FDA approval

UCB announces NAYZILAM® midazolam nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.NAYZILAM® midazolam nasal spray is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity i.e., seizure clusters, acute repetitive... See more
 
UCB [BE0003739530/UCB]   
[02/05/2019]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.Notifications referring to situation on 26 April 2019 and 30 April 2019Threshold crossed: 5%Latest holding: 5.27%Brussels Belgium, 2 May 2019 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received two... See more
 
UCB [BE0003739530/UCB]   
[02/05/2019]

UCB : UCB Media Room: anti-tau immunotherapy in scientific journal 'Brain'

UCB and University of Lille antitau immunotherapy research highlighted in prestigious international scientific journal ‘Brain’Research demonstrates potential for antitau immunotherapy in treatment of Alzheimers and other taudriven diseases including progressive supranuclear palsy PSPFindings, combined with previous in vitro research, highlight important differences between tau... See more
 
UCB [BE0003739530/UCB]   
[25/04/2019]

UCB : UCB Media Room: AGM 2019

UCBs General Meeting of ShareholdersFor financial year 2018:Gross dividend of € 1.21 per share 2.5%, payable 30 April 2019All agenda items put to vote approvedBrussels Belgium, 25 April 2019 – 18:00 CEST – regulated information Today, UCB held its Annual General Meeting of Shareholders AGM. At the AGM, 143 259 561 shares 76.07% of shares entitled to vote were represented. During the... See more
 
UCB [BE0003739530/UCB]   
[25/04/2019]

UCB : UCB Media Room: Cimzia at SPIN

New Data Showcases the Value of CIMZIA® certolizumab pegol in Patients with Psoriasis96week safety data from Phase 3 CIMPASI1, CIMPASI2 and CIMPACT studies confirm positive longterm safety profile of CIMZIA® certolizumab pegol in moderatetosevere plaque psoriasisFirst presentation of nail disease data from Phase 3 psoriasis studies demonstrate that 66.2% of patients achieved total resolution of... See more